Print  |  Close

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Active: Yes
Cancer Type: Lung Cancer NCT ID: NCT06767514
Trial Phases: Phase III Protocol IDs: SMT112-3007 (primary)
NCI-2025-01500
Eligibility: 18 Years and older, Male and Female Study Type: Treatment
Study Sponsor: Summit Therapeutics
NCI Full Details: http://clinicaltrials.gov/show/NCT06767514

Summary

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with
high PD-L1. Evaluating overall survival and progression free survival.

Treatment Sites in Georgia

Piedmont Cancer Institute - Atlanta
1800 Howell Mill Road
Suite 800
Atlanta, GA 30318
678-298-3238
www.piedmontcancerinstitute.com



Piedmont Cancer Institute - Fayetteville
1267 Highway 54 West
Suite 4200
Fayetteville, GA 30214
678-298-3238
www.piedmontcancerinstitute.com



Piedmont Cancer Institute - Newnan
775 Poplar Road
Suite 310
Newnan, GA 30265
678-298-3238
www.piedmontcancerinstitute.com



Piedmont Cancer Institute – Sandy Springs
755 Mount Vernon Hwy
Suite 320
Atlanta, GA 30328
www.piedmontcancerinstitute.com



Piedmont Cancer Institute - Stockbridge
290 Country Club Drive
Suite 100
Stockbridge, GA 30281
678-298-3238
www.piedmontcancerinstitute.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.